{"id":10360,"date":"2020-07-23T18:59:40","date_gmt":"2020-07-23T13:29:40","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=10360"},"modified":"2021-07-24T12:58:01","modified_gmt":"2021-07-24T07:28:01","slug":"recent-pharma-happenings-for-olema-boehringer-t3-pharma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma","title":{"rendered":"Olema raises $54M; T3 Pharma bags $27M to advance bacterial cancer therapy program; Biofourmis and Chugai&#8217;s Collaboration; A new study on averting heart attack"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a043b540ca55\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a043b540ca55\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma\/#Olema_Oncology_raises_USD_54_Million_for_breast_cancer_program\" >Olema Oncology raises USD 54 Million for breast cancer program<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma\/#Averting_heart_attacks_by_changing_how_platelets_respond_to_blood_flow_stress\" >Averting heart attacks by changing how platelets respond to blood flow stress<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma\/#Boehringer_backs_T3_to_take_bacterial_cancer_therapy_into_the_clinic\" >Boehringer backs T3 to take bacterial cancer therapy into the clinic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma\/#Biofourmis_Chugai_to_develop_wearable_for_digitally_measuring_endometriosis_pain\" >Biofourmis, Chugai to develop wearable for digitally measuring endometriosis pain<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Olema_Oncology_raises_USD_54_Million_for_breast_cancer_program\"><\/span><strong>Olema Oncology raises USD 54 Million for breast cancer program<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&amp;D efforts in other areas.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The capital will bankroll a phase 1\/2 study of the asset, OP-1250, as a single agent. Olema Oncology will assess the drug, a complete estrogen receptor antagonist, in patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/er-her2-ve-breast-cancer-market\"><strong>ER-positive, HER2-negative breast cancers<\/strong><\/a> that have come back despite other treatments or that have spread locally or to other parts of the body.<\/p>\n\n\n\n<p>The phase 1\/2 dose-escalation trial is scheduled for the second half of 2020. The studies combining OP-1250 with other targeted breast cancer treatments will follow as per the company.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Averting_heart_attacks_by_changing_how_platelets_respond_to_blood_flow_stress\"><\/span><strong>Averting heart attacks by changing how platelets respond to blood flow stress<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Existing clot busters prevent a <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-heart-failure-ahf-market\"><strong>heart attack<\/strong><\/a> by indiscriminately stopping platelet function, hence growing the risk of uncontrolled bleeding.<\/p>\n\n\n\n<p>Now, a research team that is led by Monash University in Australia has searched a way to target platelet activation in a way that appears to specifically address the pathological clumping of blood without meddling with normal processes that inhibit uncontrolled bleeding.<\/p>\n\n\n\n<p>In a new study that is published in Science Translational Medicine, the scientists showed that preventing a protein called PI3KC2a could alter how platelets react to a change in blood flow that can promote the formation of clots, which is a common cause of heart attack or <a href=\"https:\/\/www.delveinsight.com\/report-store\/ischemic-stroke-market\"><strong>stroke<\/strong><\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Boehringer_backs_T3_to_take_bacterial_cancer_therapy_into_the_clinic\"><\/span><strong>Boehringer backs T3 to take bacterial cancer therapy into the clinic<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>T3 Pharmaceuticals has raised USD 27 million to take its lead bacterial cancer therapy into the clinic. Boehringer Ingelheim Venture Fund (BIVF) co-led the round with the support of other existing investors.<\/p>\n\n\n\n<p>In recent years, T3 has worked to commercialize research into the role of bacterial type III secretion that can play in the delivery of proteins to intracellular targets. The approach takes over a bacterial mechanism for getting materials into human cells to turn microorganisms into delivery vehicles that are capable of hitting intracellular targets.<\/p>\n\n\n\n<p>T3 is applying the technology to solid tumors, a group of diseases, which have intracellular targets that are hard to hit with some other modalities. The Swiss biotech has designed its bacterial delivery vehicles to accumulate and replicate at solid tumour sites. In theory, the immune system will eradicate bacteria found in healthy tissues, enabling T3 to deliver deadly doses to tumors without causing extreme harmful events.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biofourmis_Chugai_to_develop_wearable_for_digitally_measuring_endometriosis_pain\"><\/span><strong>Biofourmis, Chugai to develop wearable for digitally measuring endometriosis pain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Biofourmis is collaborating with Chugai Pharmaceutical to develop a digital and objective method for clinically assessing a person\u2019s pain, and they are commencing with a focus on <a href=\"https:\/\/www.delveinsight.com\/report-store\/endometriosis-pain-market\"><strong>endometriosis<\/strong><\/a>.<\/p>\n\n\n\n<p>The difficult-to-diagnose, yet still affecting one in 10 women of reproductive age, endometriosis is caused by the growth of epithelial cells outside of the uterus, leading to pelvic pain and potential infertility.<\/p>\n\n\n\n<p>However, the severity of pain can vary daily and present in different ways, making it hard for some patients to communicate their symptoms to healthcare professionals effectively.<\/p>\n\n\n\n<p>It is using its digital platform and artificial intelligence algorithms, Biofourmis and Chugai goal to evaluate data from a wearable biosensor, in search of patterns, which could be used to quantify endometriosis pain effectively.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Olema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&amp;D efforts in other areas.&nbsp;&nbsp; The capital will bankroll a phase 1\/2 study of the asset, OP-1250, as a single agent. Olema Oncology will assess the drug, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10377,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18582,6265,127,18583,762,18585,18584,420,18581,6790,5789],"industry":[17225],"therapeutic_areas":[17242,17228,17411],"class_list":["post-10360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biofourmis","tag-boehringer","tag-breast-cancer","tag-chugai","tag-endometriosis","tag-heart-attacks","tag-her2-negative-breast-cancers","tag-news","tag-olema-oncology","tag-recent-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-oncology","therapeutic_areas-womens-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>T3 raises $27M; Olema bags $54M; Biofourmis&#039;s pact; Heart Attack study<\/title>\n<meta name=\"description\" content=\"Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&amp;D efforts in breast cancer program &amp; other areas..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"T3 raises $27M; Olema bags $54M; Biofourmis&#039;s pact; Heart Attack study\" \/>\n<meta property=\"og:description\" content=\"Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&amp;D efforts in breast cancer program &amp; other areas..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-23T13:29:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/23185804\/recent-pharma-news-and-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"T3 raises $27M; Olema bags $54M; Biofourmis's pact; Heart Attack study","description":"Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in breast cancer program & other areas..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma","og_locale":"en_US","og_type":"article","og_title":"T3 raises $27M; Olema bags $54M; Biofourmis's pact; Heart Attack study","og_description":"Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in breast cancer program & other areas..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-07-23T13:29:40+00:00","article_modified_time":"2021-07-24T07:28:01+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/23185804\/recent-pharma-news-and-update.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma","name":"T3 raises $27M; Olema bags $54M; Biofourmis's pact; Heart Attack study","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/23185804\/recent-pharma-news-and-update.jpg","datePublished":"2020-07-23T13:29:40+00:00","dateModified":"2021-07-24T07:28:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in breast cancer program & other areas..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-olema-boehringer-t3-pharma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/23185804\/recent-pharma-news-and-update.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/23185804\/recent-pharma-news-and-update.jpg","width":772,"height":482,"caption":"recent-pharma-news-and-update"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/07\/23185804\/recent-pharma-news-and-update-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biofourmis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Boehringer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chugai<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Endometriosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Heart Attacks<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HER2 Negative Breast Cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Olema Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biofourmis<\/span>","<span class=\"advgb-post-tax-term\">Boehringer<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Chugai<\/span>","<span class=\"advgb-post-tax-term\">Endometriosis<\/span>","<span class=\"advgb-post-tax-term\">Heart Attacks<\/span>","<span class=\"advgb-post-tax-term\">HER2 Negative Breast Cancers<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Olema Oncology<\/span>","<span class=\"advgb-post-tax-term\">recent news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jul 23, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jul 23, 2020 6:59 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"recent-pharma-news-and-update","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=10360"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/10360\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/10377"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=10360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=10360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=10360"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=10360"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=10360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}